Man

Lilian Soto Saez

Rheumatologist

CLINICAL HOSPITAL OF UNIVERSIDAD DE CHILE

Santiago, Chile

Líneas de Investigación


Rheumatoid arthritis (RA) pathogenesis; Action mechanisms and effects of biologic drugs for RA; Biological therapies in rheumatology; B cell alterations in autoimmunity; Biology of tolerogenic dendritic cells; Tolerance induction; Antigen discovery.

Educación

  •  Medical Surgeon, UNIVERSIDAD DE CHILE. Chile, 1997
  •  Medical Internist, UNIVERSIDAD DE CHILE. Chile, 2000
  •  Subspecialist in Rheumatology, UNIVERSIDAD DE CHILE. Chile, 2003

Experiencia Académica

  •   Assistant Professor Part Time

    UNIVERSIDAD DE CHILE

    Faculty of Medicine

    SANTIAGO, Chile

    2002 - A la fecha

Experiencia Profesional

  •   RHEUMATOLOGIST Part Time

    CLINICAL HOSPITAL OF UNIVERSIDAD DE CHILE

    SANTIAGO, Chile

    2003 - A la fecha

  •   TECHNICAL DIRECTOR Part Time

    INTERIN LTDA

    SANTIAGO, Chile

    2012 - A la fecha

  •   RHEUMATOLOGIST / CLINICAL RESEARCHER Part Time

    DERMACROSS

    SANTIAGO, Chile

    2014 - A la fecha

Premios y Distinciones

  •   Award “Dr. Antonio Reginato” to the Best Scientific Work – Basic Category

    Chilean Society of Rheumatology

    Chile, 2011

    Award “Dr. Antonio Reginato” to the Best Scientific Work – Basic Category “Adalimumab promotes changes on T- and NK cells in rheumatoid arthritis patients” XXVIII Chilean Congress of Rheumatology, Antofagasta, CHILE.


 

Proyecto (16)

Identifying immunodominant T-cell antigen-peptides and T-cell responses in rheumatoid arthritis: A further step in the development of an antigen-specific dendritic cell-based therapy to restore self-tolerance
A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis
Péptidos autoantigénicos presentados por células dendríticas tolerogénicas: Una terapia personalizada para reinstruir el sistema inmune de pacientes con artritis reumatoide
ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y PRINCIPIO ACTIVO, DE DS-5565 EN PACIENTES CON DOLOR ASOCIADO A FIBROMIALGIA
Búsqueda de un enfoque terapéutico validado basado en células para el tratamiento de la artritis reumatoide: Identificación de marcadores específicos de tolerancia y caracterización de células dendríticas tolerogénicas activadas con monofosforil lípido A (MPLA-tDCs)
Indagando mecanismos inflamatorios y su relación con el stress oxidativo en pacientes con Fibromialgia
Randomized, controlled, doble-blind, crossover study with placebo for 52 weeks, for the evaluation of adverse effects of special interest in active systemic lupus erythematosus adults patients with positive autoantibodies and Belimumab
A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA)
Efficacy, pharmacokinesis and security of BI 695500 to rituximab in active RA patients moderate and severe: randomized study, doble-blind, of parallel groups, multiple dosis and active comparator
Fcgamma receptors and regulatory B cells: A novel network behind the immune response governing systemic sclerosis
Effects of the therapy with an anti-IL-6 receptor antibody on Th17 and Tregs cell populations in rheumatoid arthritis patients
Phase II randomized, double-blind, controlled study to evaluate the immunity responses, security and clinical efficacy of three Neovac's TNF-Kinoid dosis in RA adult patients that have presented recurrence.
Applying the knowledge on murine tolerogenic dendritic cells to the development of tolerogenic monocyte-derived dendritic cells from rheumatoid arthritis (RA) patients aimed at providing a therapeutic strategy for RA treatment
Tumor necrosis factor (TNF) in the balance of Th1/Th17 axes: Lessons from anti-TNF therapy in rheumatoid arthritis
Desarrollo de tecnologías de generación de anticuerpos monoclonales completamente humanos: producción de un prototipo contra receptores tirosina quinasa Erb B para uso de terapia selectiva en cáncer gástrico
Factores predictores de respuesta clinica al tratamiento con anticuerpos monoclonales anti-TNF-a en pacientes con artritis reumatoide

Article (13)

TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients
Treatment with Dexamethasone and Monophosphoryl lipid a removes Disease-associated Transcriptional signatures in Monocyte-Derived Dendritic cells from rheumatoid arthritis Patients and confers Tolerogenic Features
Systemic sclerosis patients present alterations in the expression of molecules involved in B-cell regulation
A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines
Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients
Weak CD4+ T-cell responses to citrullinated vimentin in rheumatoid arthritis patients carrying HLA-DR9 alleles
Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-gamma-producing NK cell and regulatory T cell subsets
The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) alpha-308 G/G promoter polymorphism
B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and Fc gamma RIIb, which are modulated by anti-tumor necrosis factor therapy
Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis
Tumour necrosis factor (TNF)alpha-308 G/G promoter polymorphism and TNF alpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis
Tumour necrosis factor-alpha (TNF-alpha) levels and influence of 2308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis
The -308 polymorphism in the tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis

Abstract (6)

ANTI-TNF THERAPY INDUCES CHANGES ON T CELLS AND NK CELLS SUB-POPULATIONS IN RHEUMATOID ARTHRITIS PATIENTS
Adalimumab, a Tumor Necrosis Factor Blockade Therapy, Decreases Th1 and Th17 Populations in Rheumatoid Arthritis Patients
Basal anti-cyclic citrullinated peptide (anti-ccp) antibodies levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab therapy in rheumatoid arthritis patients
Tumor necrosis factor-alpha levels gurrelate with a better response to adalimumab in patients with rheumatoid arthritis
TNF-alpha-308 G/G promoter polymorphism correlates with a better response to adalimumab in patients with rheumatoid arthritis
Tumor necrosis factor-alpha-308 G/G promoter polymorphism correlates with a better response to adalimumab in patients with rheumatoid arthritis.

Review (4)

The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis
Skewing dendritic cell differentiation towards a tolerogenic state for recovery of tolerance in rheumatoid arthritis
Clinical parameters and biomarkers for anti-TNF treatment prognosis in rheumatoid arthritis patients
Biological therapy based on the use of last generation monoclonal antibodies

Editorial (1)

How we can improve the predictive value of prognostic biomarkers in rheumatoid arthritis
40
Lilian Soto

Rheumatologist

Medicine

CLINICAL HOSPITAL OF UNIVERSIDAD DE CHILE

Santiago, Chile

15
Juan Aguillón

PROFESSOR

IMMUNOLOGY PROGRAM

UNIVERSIDAD DE CHILE

SANTIAGO, Chile

10
Maria Sabugo

Medico Reumatologo

Medicina

UNIVERSIDAD DE CHILE HOSPITAL CLÍNICO

Santiago, Chile

9
OCTAVIO ARAVENA

INVESTIGADOR

INSTITUTO CIENCIAS BIOMÉDICAS

UNIVERSIDAD DE CHILE

Santiago, Chile

6
MARIA MOLINA

Director

Instituto de Ciencias Biomédicas

Universidad de Chile

INDEPENDENCIA, Chile

6
Pamela Wurmann

reumatologa

medicina

universidad de chile

santiago, Chile

4
Carolina Llanos

Associate Professor

Pontificia Universidad Católica de Chile

Santiago, Chile

4
Carolina Llanos

Profesor Asociado

Inmunología Clínica y Reumatología

PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

Santiago, Chile

3
Lorena Salazar

Academico

Instituto Cs Biomédicas

Universidad Autónoma de Chile

Santiago, Chile

3
Katina Schinnerling

Profesor Investigador

Departamento de Ciencias Biológicas

Universidad Andrés Bello

Santiago, Chile

2
Daniel Bueno

Médico

Servicio de Salud metropolitano Sur

Santiago, Chile

2
Jimena Cuenca

Investigador/profesor

Facultad de Medicina

Universidad de Los Andes

Santiago, Chile

1
Flavio Salazar

Profesor titular

Instituto de ciencias biomédicas

Universidad de Chile

SANTIAGO, Chile

1
Mercedes López

Profesora Asociada

Instituto de Ciencias Biomédicas

Universidad de chile

Santiago, Chile

1
Julia Guerrero

académico

Programa Disciplinario Fisiologia y Biofisica

FACULTAD DE MEDICINA, UNIVERSIDAD DE CHILE

Santiago, Chile

1
Alexis Kalergis

Full Professor

PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE. FACULTAD DE CIENCIAS BIOLÓGICAS

Santiago, Chile

1
Alejandro Escobar

assistant professor

Institute for Research in Dental Sciences

UNIVERSIDAD DE CHILE

Santiago, Chile

1
Karina Pino

Group Leader/Associate Professor

Centro de Investigación Biomédica

Universidad de los Andes

Santiago, Chile

1
Ricardo Verdugo

Asistant Professor

Facultad de Medicina

UNIVERSIDAD DE CHILE

Santiago, Chile

1
Roberto Zúñiga

Investigador Asociado a Proyectos

Programa Disciplinario de Inmunologia

Universidad de Chile/ Facultad de Medicina

Santiago, Chile

1
Paulina García

Investigador Postdoctoral

Programa de Inmunologia

Universidad de Chile

Santiago, Chile